We’re at a strange inflection point in biomedical science. The funding is there. The talent is extraordinary. The tools — AI, single-cell sequencing, population-scale biobanks — have never been more powerful or accessible. And yet, the arc of therapeutic innovation is flattening. The number of truly novel medicines reaching patients is stagnant. The gap between technological capability and translational output is widening.
The reflexive response has been to do more of the same, only faster. More AI. More incubators. More venture studios. More “translational” offices. But what if the problem isn’t a lack of effort or ingenuity? What if the problem is architectural?
We are building 21st-century discovery on 20th-century foundations. And no amount of renovation will fix a structure that was never designed to bear the weight of modern biology.
It’s time to stop retrofitting. It’s time to rebuild.
The Renovation Illusion
Over the last two decades, we’ve watched biomedical innovation try to adapt to its own complexity by slapping on external solutions. We’ve added computational overlays to experimental workflows. We’ve digitized biology and built sophisticated tools to simulate, mine, and model. We’ve introduced accelerators and venture-backed translational engines. But in truth, we’ve mostly upgraded the plumbing of an outdated building without ever asking whether we’re in the right kind of building at all.
Every layer we add is meant to make discovery faster, leaner, more scalable. But ironically, we’ve achieved the opposite: AI platforms that produce countless unvalidated hits, translational centers that struggle to integrate basic science with clinical need, and biotech startups that collapse under the weight of their own timelines.
We have been performing architectural work with interior design tools.
We’ve treated innovation as a tooling problem, not a structural one. But the structure — the flow of information, incentives, validation, and capital — is what determines whether discovery can happen at all.
The Core Problem: Discovery Is Homeless
Today, if you generate a truly novel insight — something that challenges a dominant theory, spans multiple disciplines, or lacks an immediate commercial application — where do you take it?
The uncomfortable answer is: nowhere.
Discovery, especially of the generative kind that reshapes understanding, lives in a no-man’s-land:
- Academia rewards hypothesis-driven research and incremental publication. Funding cycles, grant structures, and institutional incentives are optimized for novelty and volume, not depth or durability. There is little room for long-horizon, integrative work, let alone replication or translation.
- Startups are built to reduce uncertainty and drive toward milestones. Their job is to convert a kernel of discovery into a monetizable asset quickly. This means prioritizing surface-level signal over systems-level understanding. Startups aren’t built to explore, they’re built to exit.
- Pharma is understandably risk-averse. With multi-billion-dollar pipelines and regulatory scrutiny, it prefers validated targets and known mechanisms. The early chaos of discovery — the messy, nonlinear exploration of biology — is something pharma looks to outsource, not own.
And so the work that doesn’t fit — discovery that is early, multi-modal, or inconveniently bold — has no institutional home. It floats between academic papers, underfunded labs, and pitch decks that try to mask uncertainty with polished narratives.
This isn’t a failure of science. It’s a failure of structure.
The Translation Mirage
The term “translational science” has become a talisman in biomedical circles. Every research center now claims to be “translational”. Every funding body wants translational impact. But what does that really mean?
In theory, translation bridges the gap between basic science and clinical utility. In practice, it often becomes an exercise in optimization, not exploration. Many so-called translational efforts merely advance ideas that are already halfway down the pipeline. They are incremental by design.
The current translational paradigm is based on a linear metaphor: bench to bedside. But biology is not linear. Discovery does not progress in predictable stages. It loops, stutters, branches, and often doubles back.
Translational science, if it’s to be real, must be recursive and systems-aware. It must acknowledge that early hypotheses need iteration, that wet-lab insights must inform computational models, and that clinical signals can reshape preclinical research.
But the way our institutions are built — siloed departments, compartmentalized data, timeboxed funding — prevents this feedback loop. Translation becomes a handoff, not a dialogue.
We’re not bridging the gap. We’re papering over it.
What Real Discovery Needs
If we accept that discovery is different from commercialization, then it follows that discovery needs its own design parameters. A true discovery engine requires a very different architecture, one that protects the exploratory spirit while embedding accountability and technical rigor.
Here’s what that looks like:
- Deep Integration of AI and Wet Lab: AI alone won’t solve drug discovery, and neither will traditional lab work in isolation. Discovery happens at the intersection, where computation and experimentation continuously inform one another.
- Institutional Patience: We need time horizons that align with the rhythms of biology. The kind of capital and governance structures that support five- or ten-year discovery cycles, not quarterly targets or hype cycles.
- Cross-Disciplinary Teaming: Discovery doesn’t happen within disciplines, it happens between them. The best discoveries come from unusual combinations: bioinformatics + pathology, systems biology + clinical epidemiology, ethics + automation.
- Built-In Reproducibility: Reproducibility must be a first-order design goal, not an afterthought. That means using version-controlled data, transparent pipelines, and structured validation frameworks from day one.
- Problem-First Culture: Instead of organizing around technologies or markets, discovery institutions should organize around biological questions. Technology serves the problem, not the other way around.
Discovery is not a stage in the pipeline. It’s an ongoing function. And it needs to be treated with the same institutional seriousness we reserve for product development or commercialization.
The Blueprint for a New Institution
What we need is not another startup or another academic center. What we need is a new kind of institution, one that exists to do discovery as a primary activity, not a transient phase.
Imagine a hybrid:
- A technology platform company, but one that refuses to rush from insight to asset.
- A systems biology institute, where computation and experiment co-evolve.
- A perpetual discovery engine, designed to ask and re-ask foundational questions as the science evolves.
- A clinical partner, capable of looping patient insights back into discovery in real time.
Such an institution would require a few radical departures from the norm:
- A new funding model, combining mission-driven capital with milestone flexibility.
- An internal validation framework, where discoveries are iterated and replicated before being exposed to external markets.
- Long-term talent alignment, where scientists and engineers are incentivized to think across years, not publications or patents.
- Governance structures that prioritize epistemic integrity — how we know what we know — over valuation milestones.
This is not a fantasy. Bits of it already exist, in rare programs at the interface of academia and biotech, or within deep-tech labs. But they are fragmented. The opportunity now is to assemble these pieces into a cohesive whole.
To build an institution, not just a company.
Why This Matters Now
The biotech slowdown is not just economic. It is epistemological. We’ve reached the limits of what our current institutions can produce. The low-hanging fruit of biology has been picked. What remains are complex, nonlinear problems: heterogeneity, plasticity, multi-modal interaction, context-dependency.
These problems require new approaches, and new environments in which those approaches can thrive.
At the same time, public trust in biomedical science is under strain. The reproducibility crisis, the failure of overhyped technologies, the lack of transparent data sharing, these are not just scientific failures. They are institutional failures.
We need to respond not by shrinking our ambition, but by rebuilding the very architecture through which biomedical knowledge is generated, validated, and translated.
Because if we don’t, we risk letting our greatest tools rot in structures too brittle to support them.
Don’t Retrofit — Rebuild
There’s a difference between evolving an old system and building a new one. What biomedical science needs right now isn’t another layer of digital paint or another translational initiative tucked inside a legacy institution. What it needs is boldness, a willingness to start again.
We must stop treating discovery as a short-term phase and start building institutions where discovery is a permanent, protected function.
That’s what we’ve built at Bioada. A platform not just for signal detection, but for signal validation, translation, and impact, all within a reproducible, end-to-end architecture.
But we don’t expect to do it alone. We believe there’s a whole new category of institution emerging, rooted in science, enabled by technology, unafraid of complexity, and built to serve medicine’s deepest challenges.
And the first step in creating that category is architectural.
It’s time to stop renovating.
It’s time to start rebuilding.